| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 11 | 2024 | 648 | 1.830 |
Why?
|
| Influenza Vaccines | 8 | 2024 | 472 | 1.610 |
Why?
|
| Hospitalization | 23 | 2024 | 1733 | 1.350 |
Why?
|
| Intubation, Intratracheal | 9 | 2024 | 291 | 1.060 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2024 | 178 | 0.930 |
Why?
|
| Critical Illness | 8 | 2024 | 595 | 0.860 |
Why?
|
| Laryngoscopes | 4 | 2023 | 68 | 0.770 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2019 | 4 | 0.670 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 21 | 0.660 |
Why?
|
| Bronchoscopy | 5 | 2019 | 157 | 0.660 |
Why?
|
| Pneumonia | 2 | 2022 | 325 | 0.640 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 35 | 0.640 |
Why?
|
| Vaccination | 9 | 2024 | 949 | 0.620 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 455 | 0.560 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 197 | 0.560 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2024 | 334 | 0.520 |
Why?
|
| Pleurisy | 1 | 2015 | 6 | 0.510 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 3 | 0.500 |
Why?
|
| Time | 1 | 2015 | 94 | 0.500 |
Why?
|
| Risk Assessment | 3 | 2015 | 3332 | 0.490 |
Why?
|
| Adult | 39 | 2024 | 29035 | 0.480 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 31 | 0.480 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 41 | 0.460 |
Why?
|
| Humans | 72 | 2024 | 123190 | 0.450 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 176 | 0.440 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2019 | 199 | 0.430 |
Why?
|
| Aged | 29 | 2024 | 19068 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2043 | 0.420 |
Why?
|
| Laryngoscopy | 3 | 2023 | 149 | 0.420 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2012 | 7 | 0.420 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 220 | 0.400 |
Why?
|
| Middle Aged | 29 | 2024 | 25976 | 0.380 |
Why?
|
| Pneumonectomy | 1 | 2012 | 127 | 0.370 |
Why?
|
| Hypoxia | 2 | 2024 | 245 | 0.370 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 457 | 0.370 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 2838 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 204 | 0.360 |
Why?
|
| Heart Arrest | 3 | 2024 | 341 | 0.360 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2019 | 75 | 0.360 |
Why?
|
| Shock | 2 | 2022 | 89 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 31 | 0.340 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 553 | 0.330 |
Why?
|
| Female | 34 | 2024 | 65427 | 0.310 |
Why?
|
| United States | 17 | 2024 | 10618 | 0.310 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 300 | 0.300 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 118 | 0.290 |
Why?
|
| Case-Control Studies | 7 | 2024 | 3260 | 0.290 |
Why?
|
| Seasons | 3 | 2024 | 303 | 0.270 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 8 | 0.260 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 161 | 0.260 |
Why?
|
| Male | 26 | 2024 | 60020 | 0.250 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1871 | 0.250 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 46 | 0.230 |
Why?
|
| Bias | 1 | 2024 | 125 | 0.230 |
Why?
|
| Polysomnography | 3 | 2019 | 137 | 0.220 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 92 | 0.220 |
Why?
|
| Influenza A virus | 1 | 2024 | 134 | 0.210 |
Why?
|
| Hemoptysis | 2 | 2021 | 22 | 0.210 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 118 | 0.210 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2820 | 0.200 |
Why?
|
| Respiratory Paralysis | 1 | 2001 | 7 | 0.200 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 8 | 0.200 |
Why?
|
| Pulmonary Atelectasis | 1 | 2001 | 14 | 0.200 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 230 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2022 | 122 | 0.190 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 106 | 0.190 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 41 | 0.190 |
Why?
|
| Hypotension | 1 | 2022 | 175 | 0.180 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 312 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6371 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 121 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2024 | 313 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 263 | 0.180 |
Why?
|
| Aneurysm | 1 | 2021 | 88 | 0.180 |
Why?
|
| Adolescent | 9 | 2024 | 19086 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2022 | 163 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1088 | 0.170 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2019 | 3 | 0.170 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 75 | 0.170 |
Why?
|
| Intensive Care Units | 3 | 2024 | 484 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 2021 | 101 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 47 | 0.170 |
Why?
|
| Mediastinitis | 2 | 2017 | 14 | 0.170 |
Why?
|
| Azithromycin | 1 | 2019 | 45 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2021 | 350 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 115 | 0.160 |
Why?
|
| Cough | 1 | 2019 | 86 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2002 | 385 | 0.160 |
Why?
|
| Home Care Services | 1 | 2018 | 67 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2019 | 357 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2024 | 6028 | 0.150 |
Why?
|
| Hospital Mortality | 4 | 2024 | 1004 | 0.150 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 26 | 0.140 |
Why?
|
| Long-Term Care | 1 | 2017 | 71 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 220 | 0.140 |
Why?
|
| Fever | 1 | 2019 | 296 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 45 | 0.140 |
Why?
|
| CA-125 Antigen | 1 | 1996 | 12 | 0.130 |
Why?
|
| Young Adult | 7 | 2024 | 8868 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 597 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2017 | 102 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 850 | 0.130 |
Why?
|
| Bacteremia | 1 | 2020 | 406 | 0.130 |
Why?
|
| Abdominal Neoplasms | 1 | 1996 | 33 | 0.130 |
Why?
|
| Oxygen | 3 | 2024 | 540 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1305 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 154 | 0.130 |
Why?
|
| Carmine | 1 | 1995 | 1 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2397 | 0.120 |
Why?
|
| Leiomyoma | 1 | 1996 | 90 | 0.120 |
Why?
|
| Parasitic Diseases | 1 | 1996 | 61 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 1995 | 18 | 0.120 |
Why?
|
| Logistic Models | 2 | 2021 | 1799 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 38 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 75 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 241 | 0.120 |
Why?
|
| Legionella | 1 | 2014 | 9 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 236 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2017 | 365 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1070 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 149 | 0.110 |
Why?
|
| Lung | 3 | 2014 | 1469 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 39 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1582 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1597 | 0.100 |
Why?
|
| Influenza B virus | 2 | 2024 | 87 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 1245 | 0.100 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1069 | 0.100 |
Why?
|
| Video Recording | 2 | 2023 | 181 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2020 | 15979 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 516 | 0.100 |
Why?
|
| Trachea | 2 | 2023 | 202 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 4508 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 264 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2108 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1586 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2125 | 0.090 |
Why?
|
| RNA | 2 | 2023 | 577 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2024 | 4708 | 0.080 |
Why?
|
| Biopsy | 1 | 2012 | 1239 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2017 | 1158 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 5047 | 0.070 |
Why?
|
| Sleep | 2 | 2019 | 348 | 0.060 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 20 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 420 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2023 | 698 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2004 | 86 | 0.060 |
Why?
|
| Masks | 1 | 2024 | 39 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 182 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 62 | 0.050 |
Why?
|
| Vincristine | 1 | 2004 | 195 | 0.050 |
Why?
|
| Bronchial Diseases | 1 | 2003 | 12 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 145 | 0.050 |
Why?
|
| Gynecology | 1 | 2024 | 127 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 213 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 5 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 300 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 6201 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 12 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1216 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 83 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2001 | 4 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 33 | 0.050 |
Why?
|
| Sarcoma | 1 | 2004 | 194 | 0.050 |
Why?
|
| Heart Septum | 1 | 2001 | 56 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 102 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 308 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 137 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 397 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 382 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 133 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1259 | 0.050 |
Why?
|
| Patient Selection | 1 | 2024 | 685 | 0.050 |
Why?
|
| Diaphragm | 1 | 2001 | 97 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 540 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 20 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3548 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 209 | 0.040 |
Why?
|
| Subclavian Artery | 1 | 2021 | 71 | 0.040 |
Why?
|
| Enterococcus | 1 | 2020 | 32 | 0.040 |
Why?
|
| Prevalence | 2 | 2023 | 2405 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 151 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 236 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 215 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 744 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 514 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1114 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 36 | 0.040 |
Why?
|
| Heart Atria | 1 | 2001 | 310 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2003 | 316 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 217 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2017 | 12102 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1588 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 502 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1102 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1167 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 234 | 0.040 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 31 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 634 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1230 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 6 | 0.040 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 6 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 390 | 0.040 |
Why?
|
| Fallopian Tube Diseases | 1 | 1997 | 12 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1997 | 21 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 1997 | 28 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 1284 | 0.030 |
Why?
|
| Critical Care | 1 | 2002 | 650 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.030 |
Why?
|
| Fistula | 1 | 1997 | 50 | 0.030 |
Why?
|
| Risk Factors | 3 | 2024 | 10001 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 164 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 606 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 254 | 0.030 |
Why?
|
| Stents | 2 | 2017 | 866 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2027 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1105 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 20 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 372 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 77 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 3050 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1404 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1133 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 28 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 314 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 753 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 46 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 183 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 272 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 499 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 100 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 33740 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1387 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2851 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 510 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 1684 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3007 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 991 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2004 | 1470 | 0.020 |
Why?
|
| Ohio | 1 | 2006 | 89 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2006 | 24 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 194 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 260 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2006 | 294 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2006 | 196 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 354 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 51 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 272 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 163 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 399 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 645 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1240 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1418 | 0.010 |
Why?
|
| Adnexal Diseases | 1 | 1997 | 23 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2001 | 1114 | 0.010 |
Why?
|